Bulbitech has raised 5,7 MNOK in an emission and 4,8 MNOK in convertible loans as part of a bridge round with existing shareholders. The capital is needed to extend the runway of the company as the validation trials in ophthalmology take longer than expected. The company expects the results of those trials by the end of October. Meanwhile the validation trials in Parkinson’s patients and patients with Ataxia are finalized. Results are expected to be published soon.
During the last months Bulbitech and a British manufacturer of optical devices managed to reach the final stage of negotiating an agreement. In order to finalize Bulbitech’s online platform, complete EMA/FDA approval and commercial scale-up Bulbitech is open for new investors to invest in the company.
Interested are invited to send an email to investor@bulbitech.com
